Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Yearly Bisphosphonate!

An interim analysis of the HORIZON study was presented at the annual meeting of the American Society of Bone and Mineral Research.

The Health Outcomes and Reduced Incidence with Zoledronic acid Once yearly (Horizon) study aimed to assess the impact of an annual dose of zoledronic acid on the rate of fractures in postmenopausal women.

The complete data are not yet available however a press release claims that the early analysis shows that results appear promising for the drug.

The obvious major drawback is that the drug is formulated as an intravenous infusion and delivering it in primary care raises challenges.

Action: The investigated indication is currently unlicensed. If a licence extension is granted the challenges presented by intravenous administration are likely to significantly limit use.

Share 'Yearly Bisphosphonate!' on Email Share 'Yearly Bisphosphonate!' on Delicious Share 'Yearly Bisphosphonate!' on Digg Share 'Yearly Bisphosphonate!' on Facebook Share 'Yearly Bisphosphonate!' on Google+ Share 'Yearly Bisphosphonate!' on reddit Share 'Yearly Bisphosphonate!' on StumbleUpon Share 'Yearly Bisphosphonate!' on Twitter

atomic-wealth

No Comments to “Yearly Bisphosphonate!”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,321 spam comments.

atomic-wealth
fond-illness
summer